128 related articles for article (PubMed ID: 1526689)
1. Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker.
Ohashi K; Sudo T; Sakamoto K; Tateishi T; Fujimura A; Kumagai Y; Shiga T; Ebihara A
Int J Clin Pharmacol Ther Toxicol; 1992 Aug; 30(8):271-4. PubMed ID: 1526689
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers.
Christensen H; Asberg A; Holmboe AB; Berg KJ
Eur J Clin Pharmacol; 2002 Nov; 58(8):515-20. PubMed ID: 12451428
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence and relative bioavailability of a new diltiazem sustained release formulation.
Scheiwe MW; Lankhaar G; Kleinbloesem CH
Arzneimittelforschung; 1996 Oct; 46(10):960-3. PubMed ID: 8931888
[TBL] [Abstract][Full Text] [Related]
4. Interaction of some drugs on the pharmacokinetics or pharmacodynamics of MPC-1304, a dihydropyridine Ca2+ antagonist.
Nakano M; Miyoshi K; Umeno Y; Yoshida K; Nishizaki J; Miyake H
Arch Int Pharmacodyn Ther; 1996; 331(2):109-23. PubMed ID: 8937623
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses.
Schwarzwald CC; Sams RA; Bonagura JD
J Vet Pharmacol Ther; 2006 Jun; 29(3):165-71. PubMed ID: 16669860
[TBL] [Abstract][Full Text] [Related]
6. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
[TBL] [Abstract][Full Text] [Related]
7. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.
Varis T; Backman JT; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Mar; 67(3):215-21. PubMed ID: 10741623
[TBL] [Abstract][Full Text] [Related]
8. Comparison of bioavailability and pharmacodynamics of diltiazem from two pharmaceutical preparations.
Dange SV; Nandal DH; Gokhale VS; Shah KU; Kadam DB
Indian J Physiol Pharmacol; 1992 Jul; 36(3):205-8. PubMed ID: 1473854
[TBL] [Abstract][Full Text] [Related]
9. Gender related pharmacokinetics of diltiazem in healthy subjects.
Sáenz-Campos D; Bayés MC; Martin S; Barbanoj MJ; Jané F
Int J Clin Pharmacol Ther; 1995 Jul; 33(7):397-400. PubMed ID: 7582396
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the daily variation in blood pressure and pharmacokinetics after single or repeated administration of clentiazem to patients with essential hypertension.
Suzuki S; Mori M; Kusano S
Arzneimittelforschung; 1992 Apr; 42(4):533-9. PubMed ID: 1642678
[TBL] [Abstract][Full Text] [Related]
11. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone.
Lamberg TS; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Jun; 63(6):640-5. PubMed ID: 9663178
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics and pharmacodynamics of diltiazem floating tablets].
Gu TH; Chen SX; Zhu JB; Song DJ; Guo JZ; Hou HM
Zhongguo Yao Li Xue Bao; 1992 Nov; 13(6):527-31. PubMed ID: 1302441
[TBL] [Abstract][Full Text] [Related]
13. The interaction of diltiazem with lovastatin and pravastatin.
Azie NE; Brater DC; Becker PA; Jones DR; Hall SD
Clin Pharmacol Ther; 1998 Oct; 64(4):369-77. PubMed ID: 9797793
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine.
Laganière S; Davies RF; Carignan G; Foris K; Goernert L; Carrier K; Pereira C; McGilveray I
Clin Pharmacol Ther; 1996 Sep; 60(3):255-64. PubMed ID: 8841148
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension.
Watanabe H; Kosuge K; Nishio S; Yamada H; Uchida S; Satoh H; Hayashi H; Ishizaki T; Ohashi K
Life Sci; 2004 Dec; 76(3):281-92. PubMed ID: 15531380
[TBL] [Abstract][Full Text] [Related]
16. Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age.
Bianchetti G; Billy S; Ascalone V; Saivin S; Houin G; Rosenzweig P
Int J Clin Pharmacol Ther; 1996 May; 34(5):195-201. PubMed ID: 8738855
[TBL] [Abstract][Full Text] [Related]
17. Absorption, plasma concentration, and excretion after single administration of 14C-(+-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5- nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate hydrochloride in rats and dogs.
Matsunaga T; Tanabe H; Mochizuki T; Okabe K; Arizono H; Taneda M; Sato H; Ishii S; Sato J; Kiyoki M
Arzneimittelforschung; 1992 Apr; 42(4):519-25. PubMed ID: 1642676
[TBL] [Abstract][Full Text] [Related]
18. Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits.
Choi JS; Li X
Int J Pharm; 2005 Jun; 297(1-2):1-8. PubMed ID: 15907592
[TBL] [Abstract][Full Text] [Related]
19. A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure.
Mahgoub AA; El-Medany AH; Abdulatif AS
Saudi Med J; 2002 Jun; 23(6):725-31. PubMed ID: 12070557
[TBL] [Abstract][Full Text] [Related]
20. Effects of a new calcium channel blocker, MPC-1304, on blood pressure, serum lipoproteins and serum carbohydrate metabolism in patients with essential hypertension.
Sasaki J; Kajiyama G; Kusukawa R; Shichiri M; Sunaga T; Mashiba H; Tanaka N; Nonaka K; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jun; 33(6):366-70. PubMed ID: 7582390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
